• Skip to main content
  • Skip to secondary menu
  • Skip to footer
Addiction Treatment Forum

Addiction Treatment Forum

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

  • Newsletter
  • Addiction Resources
  • Methadone
  • Buprenorphine
  • Patient Brochures
  • Events
  • Related Websites

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

nerve cell (neuron)

Study: Long-term Abstinence Restores Impaired Brain Function and Structure in Patients With Heroin Use Disorder, but Questions Remain

Barbara Goodheart, ELS
June 24, 2022

When Agatha Christie’s famous Belgian detective, Hercule Poirot, attributed his investigative success to “the little grey cells”—components of the brain’s grey matter—he may well have been correct. He usually was. Today, neuroscientists delving into the comparatively neglected “other half of the brain” are defining the highly important roles of white matter. They’ve found that in…

Continue Reading Study: Long-term Abstinence Restores Impaired Brain Function and Structure in Patients With Heroin Use Disorder, but Questions Remain

DOJ Issues Guidance Underscoring ADA Protections for People Taking Methadone or Buprenorphine

Alison Knopf
June 8, 2022

The federal Department of Justice has ordered repeatedly that people in treatment or recovery on medications to treat opioid use disorder are protected by the Americans with Disability Act (ADA). This spring, the federal government issued guidance specifying this, and noting that entities covered by the ADA include the workplace, healthcare organizations, and the criminal…

Continue Reading DOJ Issues Guidance Underscoring ADA Protections for People Taking Methadone or Buprenorphine

Expanding Access to Methadone Treatment

Alison Knopf
June 8, 2022

A recent article based on the two-day methadone workshop by the National Academies of Science, Engineering, and Medicine distills several of the messages of that workshop: extending take-home flexibilities and allowing physician prescribing are two of the top ones (for more on that workshop, see https://atforum.com/2022/03/nasem-methadone-expand-access-primary-care/). The report, published in Health Affairs May 27, is…

Continue Reading Expanding Access to Methadone Treatment

AT Forum Newsletter – Recent Articles

AATOD: No Pharmacy Dispensing of Methadone, Except for Stable Patients Currently in OTPs

Alison Knopf
May 24, 2022

In a policy document on “Methadone Reform” updated this spring by the American Association for the Treatment of Opioid Dependence (AATOD), the organization has clearly noted that dosing in the clinic is associated with improved treatment retention, and that pharmacy distribution has been linked to diversion and to concomitant getting rid of methadone as a…

Continue Reading AATOD: No Pharmacy Dispensing of Methadone, Except for Stable Patients Currently in OTPs

Why 8 Milligrams of Naloxone Should be Given in all Opioid ODS, STAT: Fentanyl

Alison Knopf
May 24, 2022

In the era of illicit fentanyl, multiple doses of naloxone are sometimes needed to reverse opioid overdoses, a recent literature review published in Substance Abuse has confirmed. Reports of the need for multiple doses of the 2-mg version have long been noticed by first responders, and the article confirms those reports. However, giving someone one…

Continue Reading Why 8 Milligrams of Naloxone Should be Given in all Opioid ODS, STAT: Fentanyl

Study: “Just Give Them a Choice!”—What Patients Think About Starting Buprenorphine or Methadone in the ED

Barbara Goodheart, ELS
May 24, 2022

Emergency department (ED) clinicians could start patients with opioid use disorder (OUD) on the road to life-saving recovery by beginning buprenorphine treatment during an ED visit. But many patients aren’t given a prescription when they leave the ED. Why is this? Research on treating OUD in the ED has tended to focus on clinician-reported barriers,…

Continue Reading Study: “Just Give Them a Choice!”—What Patients Think About Starting Buprenorphine or Methadone in the ED

APA Meeting to Feature New President Discussing Buprenorphine

Alison Knopf
May 23, 2022

The American Psychiatric Association annual meeting, gathering live for the first time since 2019, will be in New Orleans May 21-25. The first sold-out session was a day-long seminar on treating opioid use disorder (OUD) with buprenorphine, conducted by new APA president Petros Levounis, M.D., an addiction medicine physician, and colleagues. Levounis is professor and…

Continue Reading APA Meeting to Feature New President Discussing Buprenorphine

On track for major changes: SAMHSA programs

Alison Knopf
May 22, 2022

The Substance Abuse and Mental Health Services Administration (SAMHSA) is in the middle of a Congressional move to change it. On May 6, Rep. Frank Pallone, Jr. (D–NJ) and Rep. Cathy McMorris Rodgers (R–Wash.), chairman and ranking member of the House Energy and Commerce Committee, released proposed legislation that would reauthorize the agency and revamp…

Continue Reading On track for major changes: SAMHSA programs

Mobile methadone in New York

Alison Knopf
April 29, 2022

The unrolling story of methadone vans in New York is being enthusiastically assisted by Allegra Schorr. She heads the Coalition of Medication-Assisted Treatment Providers and Advocates (COMPA). COMPA represents New York State’s opioid treatment programs (OTPs) which are focused on making methadone more accessible to more patients. We talked to Schorr earlier this month about…

Continue Reading Mobile methadone in New York

Footer

Addiction Treatment Forum is produced by an independent medical communications agency. Commercial advertising is not accepted.
Published by Clinco Communications, Inc.
About Us
Contact Us
Privacy Policy
Terms of Use
Follow Us

This educational resource is supported by Hikma Pharmaceuticals USA Inc.

Sign up for News!

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Clinco Communications, Inc., 1808 N. Arlington Heights Road, Arlington Heights, IL, 60004, http://www.atforum.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

© 2022 Addiction Treatment Forum · All Rights Reserved